Alamethicin is reported to be a peptide of 18 amino acids, 17 of which form a closed ring which has a side chain, glutmine-18. By using n.m.r. spectroscopy we have found that this structure is incorrect. Alamethicin is a linear peptide composed of the 18 amino acids, in the sequence previously published, but in addition it has two new end-groups. The sequence is:
Pro-Mea-~a-Mea-Ala-Gln-Mea-Val-Mea-Gly-~u-Mea-Pro-Val-M~-M~-Glu-Gln where Mea is methylalanine. There is a p-phenylalaninol, -NH-CH(CH2Ph)-CH20H, attached to the y-carboxylate of glutamate-1 7, and proline-1 is N-blocked by an N-acetylated methylalanine. The N-acetyl group is probably in the form of a five-membered ring back-linked to the proline:
Thus alamethicin has one negative and one positive charge distributed at opposite ends of the molecule, as indicated by the binding of both anions and cations. 553rd MEETING, LONDON
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The structure has been proved as follows.
(i) A complete analysis of the proton n.m.r. spectrum of alamethicin and a number of its hydrolysates. In these analyses it proved to be necessary to use lanthanide shift and relaxation probes bound at the negative end of alamethicin and to use [Cr(CN),I3-as a relaxation probe of the positive end of the molecule.
(ii) Separation of 8-phenylalaninol and N-acetylmethylalanine from suitable hydrolysates of the peptide and their characterization by n.m.r. methods.
(iii) Direct comparison of the hydrolysis products with known compounds prepared independently. (We thank Dr. M. R. Alecio for his help in this work.)
Theusual preparations of alamethicin also contain a second peptide called alamethicin F.50 to distinguish it from the major product F.30 described above. It differs from alamethicin F.30 in that the free carboxyl group has been converted into the amide. Alamethicin F.50 was shown to have the same blocking groups as F.30. As far as can be judged from the literature all work on alamethicin has been carried out on a mixture of the two components. (Dr. J. Melling has been of vital assistance in the work distinguishing these two peptides.)
Interest in alamethicin centres on its ability to transport cations through biological and artificial lipid membranes. In the artificial systems the transport properties of alamethicin mimic closely those of nerve action. Explanations on the basis of the previous structure of alamethicin must be rejected. A simplemodel which suggests itself now is that alamethicin, which is 5 d n m (50-60A) long, forms head-to-taii n-mers in the membranes which extend from one side of the membrane to the other. An n-mer can be arranged so that it forms a hydrophilic internal channel and a hydrophobic exterior. Uptake ofcations can occur, see below, at the carboxylateresidue. A fully-loaded channel could utilize the orientated carbonyl groups of the peptide bonds in the middle of the chain. The observed field dependence of conductance could depend on a control over orientation of the molecule in the different bound states. It is noteworthy that alamethicin is a very large dipole, and transports both anions and cations.
The metal-binding site at the carboxylate end of alamethicin was readily found by using lanthanide probes. Binding is dependent on pH both in strength and in structure so that ion transport is undoubtedly controlled by pH, although it is not known if alamethicin will transport protons. The following groups bind the metal ions at high pH:
-OH of 8-phenylalaninol ; glutamine-18 carboxylate; methylalanine-1 5 carbonyl; proline-1 3 carbonyl ; and possibly glutamate-1 7 carbonyl.
At low pH the binding to proline-13 is lost and the binding to the region of glutamine-18 and glutamate-17 is modified. The site has similarities to the sites of calcium ionophores.
We are deeply indebted to Dr. J. Melling (Porton M.R.E.) who prepared all the alamethicin samples and to Dr. R. E. Offord and Dr. J. Priddle for assistance at various stages with the peptide chemistry, and we thank Dr. G. Young for helpful discussion. The work is supported by a grant from the Wellcome Trust and by both the Medical and the Science Research Councils. R. J. P. W. is a member of the Oxford Enzyme Group. Adenine nucleotide translocation in mitochondria is the process by which adenine nucleotide molecules are exchanged specifically in a 1 : 1 ratio between the inner and outer compartments. The translocase that mediates the exchange is situated in the inner membrane. Two inhibitors of the translocase of mammalian mitochondria are atractyloside (Kemp & Slater, 1964; PfaiT et ul., 1965) and bongkrekic acid (Henderson & Lardy,
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